Key Insights Significantly high institutional ownership implies Bristol-Myers Squibb's stock price is sensitive ...

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

This was partly offset by a 1% rise in the company’s revenue from $46 billion to $47 billion over the same period; and a 4.1% ...

Here are two brilliant options along those lines: CVS Health ( CVS 0.44%) and Bristol Myers Squibb ( BMY -1.03%). Find out ...

Bristol-Myers Squibb has demonstrated its commitment to shareholders with ... Overall, the mood on Wall Street is tepid for ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

Shares of Bristol Myers Squibb Co. BMY shed 1.34% to $59.02 Tuesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500 Index SPX falling 0.29% to 5,983.99 ...

Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

Shares of Bristol Myers Squibb Co. BMY inched 0.90% higher to $55.95 Tuesday, on what proved to be an all-around positive ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

Bristol-Myers Squibb's Cobenfy comes out as the major beneficiary and ... Analyst’s Disclosure: I/we have a beneficial long ...